# Tester Gate 2 Review — Incomplete Expiry Partition Fix

Date: 2026-10-04
Developer submission reviewed: phase-2-data-developer@02cfa7475a2dd0d16113e77a507eaf6136c6f5cf

**Decision: GATE 2 NOT PASSED**

## Independent findings

1. The latest completed workflow before this submission produced one trade for expiry 2026-07-28.
2. Its source coverage ended on 2026-07-02, so the engine previously treated an incomplete partition as an early exit.
3. That violates the strategy specification requiring a 32-calendar-day entry window and monitoring through the final pre-expiry session.
4. The developer has added a validation rule and regression tests so a materially incomplete expiry partition is rejected.
5. The new CI run for the developer submission was queued at review time and must complete successfully before this code fix is accepted.
6. The underlying Hugging Face dataset describes expiry-partitioned 1-minute OHLCV(+OI) option data and explicitly notes partial option coverage; its advertised structure alone does not establish full 32-DTE coverage. This must be demonstrated expiry-by-expiry.

## Required gate conditions

- New CI run must pass unit tests.
- Backtest must not create a trade from an incomplete expiry partition.
- candidate_status.csv must explicitly distinguish incomplete coverage from valid skips.
- A final data source must demonstrate complete 32-DTE-to-pre-expiry coverage for the cycles included in the performance sample.
- Provenance must remain immutable: dataset revision, retrieval time, code SHA and file hashes.
- Independent source/overlap validation remains required before Gate 2 can pass.
- No performance metrics from the invalid one-trade sample may be promoted.

## Tester conclusion

The correction is directionally correct and removes a material early-exit validity defect, but Gate 2 remains closed because a defensible complete historical sample has not yet been demonstrated.

**Tester instruction to developer:** keep Phase 2 open; inspect the new CI result, obtain/validate a source with full cycle coverage, and resubmit the complete evidence for another independent Gate 2 review.
